NL|15 – 21 October 2016
Today REVIFAST®CARDIO was presented to all pharmaceutical representatives, the new product by S&R Farmaceutici, the brainchild of its Research and Development Division that will further enrich the Company’s extensive treatment offering.
Revifast®cardio contains Revifast®, the revolutionary and patented highly bioavailable Resveratrol, at last fully exploiting the great therapeutic cardiovascular potential of one of the most promising and extensively studied natural bioactive molecules.
Revifast® overcomes the problem of solubility experienced with resveratrol, considerably increasing dissolution speed and therefore bioavailability. The improved solubility of Revifast® results in a significant increase in plasma concentration of the polyphenol compared to Resveratrol.
• 3.3 times more bioavailability
• Peak plasmatic concentration 30% greater
• Remains in plasma 4 times longer
REVIFAST®CARDIO also combines all the benefits of Resveratrol with the effective action of Monacolin K which significantly lowers Total Cholesterol, Triglicerides and LDL Cholesterol, without altering liver, kidney or muscle function and glycaemia levels.
REVIFAST®CARDIO, with its unique and innovative characteristics, presents itself as the new ally in cardiovascular disease prevention.
Sorry, the comment form is closed at this time.